Abstract Background: Platelets have been increasingly recognized as an important component of innate and adaptive immunity. Platelet response in antimicrobial host defense is similar, in many ways, to the leukocyte response: both cell types contain antimicrobial peptides that act against a broad range of pathogens.
Introduction
Platelets have been increasingly recognized as an important component of innate and adaptive immunity. Platelet response in antimicrobial host defense is similar, in many ways, to the leukocyte response: both cell types contain antimicrobial peptides that act against a broad range of pathogens. After platelets and neutrophils are activated, they accumulate at the site of infection to produce direct contact between their antimicrobial peptides and invading bacteria. Leukocytes need to phagocytize bacteria to achieve interaction with intracellular peptides; platelets can also internalize microorganisms into phagosome-like vacuoles, enhancing pathogen clearance. Antimicrobial peptides from both cells exert a rapid, potent, and direct antimicrobial effect that contributes to limiting the infection [1] .
Clinicians have always evaluated the degree of leucocytosis in patients with pneumonia as an indication of systemic inflammatory response and severity of disease. Thrombocytopenia is also a recognized marker of poor outcomes in patients with pneumonia due to the association of low platelet counts with disseminated intravascular coagulation and severe sepsis. Abnormalities in the coagulation system can be due to low as well as high platelet count. However, the association between thrombocytosis and clinical outcomes in adult patients with community-acquired pneumonia (CAP) has not been investigated [2] .
Considering that platelets play a crucial role in antimicrobial host defenses and the coagulate system, it is hypothesized that an abnormal platelet count may be an important marker to assess severity of disease in patients with CAP [3, 4] .
Subjects and methods
This was a prospective study of the relation between platelet count abnormality and the severity and outcome of community-acquired pneumonia cases. The study included 40 cases of CAP admitted at the Chest Department and Respiratory ICU at Ain Shams University Hospital, as well as, Chest Department and Respiratory ICU at Ain Shams University Specialized Hospital.
All cases were subjected to the following: 
Study definitions
CAP is defined as the presence of a new pulmonary infiltrate on chest radiograph at the time of hospitalization associated with at least one of the following: (1) new or increased cough, (2) an abnormal temperature (<35.6°C or > 37.8°C), (3) an abnormal serum leukocyte count (leucocytosis, left shift, or leucopenia defined by local laboratory values). CAP severity was measured using CURB-65 scoring tool.
Hypotension is defined as a systolic blood pressure <90 mmHg or diastolic blood pressure <60 mmHg.
Alteration of gas exchange is defined as Pa O2 <60 mmHg or Pa O2/FIO 2 < 300 or O2 saturation <90%.
Thrombocytopenia and thrombocytosis are defined as platelet counts <150,000/L or >400,000/L, respectively.
Patients with immunosuppression, neoplasms, active TB or hematologic diseases were excluded.
Statistical methodology
Analysis of data was done by IBM computer using SPSS (statistical program for social science version 16) as follows:
Description of quantitative variables as mean, SD and range. Description of qualitative variables as number and percentage. Fisher exact test was used instead of chi-square test when one expected cell or more less than or equal 5. Validity parameters from ROC (receiver operator characteristic curve) Sensitivity = true ve +/true + ve + false -ve. = ability of the test to detect + ve cases. Specificity = true -ve/true-ve + false + ve. = ability of the test to exclude negative cases. PPV (positive predictive value) = true+/true + ve ± false + ve. =% of true + ve cases to all positive. NPV = true-/true-ve + false -ve. =% of the true -ve to all negative cases. Accuracy = true + ve + true-ve/grand total [6] .
P value > 0.05 insignificant. P 6 0.05 significant. P < 0.01 highly significant.
Results Table 1 shows that 75% of the enrolled patients were males and 25% were females, the age ranged from 17 to 84 years with a mean of 60 ± 17 years, the length of hospital stay ranged from 3 to 25 days with a mean of 11.5 ± 5 days, 80% of the patients presented with lobar consolidation while the other 20% presented by multilobar consolidation, 50% of the included patients had type II respiratory failure, 30% had type I respiratory failure, while only 20% of the patients did not have respiratory failure, 47.5% of the patients did not develop any complications, 30% developed respiratory complications, 17.5% developed non-respiratory complications and 5% developed both respiratory and non-respiratory complications, and finally, 42.5% of the patients survived while 57.5% of them died. Table 2 shows that there was no significant statistical relation between the different variables (gender, site of pneumonia, presence or absence of respiratory failure, the need for mechanical ventilation) and the mean of platelet count by using one way ANOVA test. Table 3 shows that there was no significant statistical correlation between the mean of platelet count versus age and length of hospital stay by using Spearman correlation. Table 4 shows that there was a significant statistical relation between the occurrence of respiratory complications and both thrombocytopenia and thrombocytosis by using chi-square test. Table 5 shows that that there was a significant statistical relation between both thrombocytopenia and thrombocytosis and the CURB65 score as a score for severity of CAP by using one way ANOVA test. Table 6 shows that there was a significant statistical relation between both thrombocytopenia and thrombocytosis and mortality among the patients with CAP by using chi-square test. Table 7 shows that platelet count is considered better positive than a negative predictor value to the outcome by using the receiver operating curve (ROC curve).
Discussion
Clinicians have always evaluated the degree of leucocytosis in patients with pneumonia as an indication of systemic inflammatory response and severity of disease. Thrombocytopenia is also a recognized marker of poor outcomes in patients with pneumonia, due to the association of low platelet counts with disseminated intravascular coagulation and severe sepsis [3] .
Platelets are important inflammatory cells that can undergo chemotaxis and are able to release numerous pro inflammatory molecules. In patients with CAP, there is an association between levels of inflammatory cytokines and severity of disease. It can be theorized that thrombocytosis may favor an exaggerated systemic inflammatory response that, in turn, produces poor outcomes in patients with CAP [7] .
This study was a prospective one about the relation between platelet count abnormality and the severity and outcome of community-acquired pneumonia cases. The study included 40 cases of CAP admitted at the Chest Department and Respiratory ICU at Ain Shams University Hospital, as well as, the Chest Department and Respiratory ICU at Ain Shams University Specialized Hospital.
The results showed that 75% of the enrolled patients were males and 25% were females, the age ranged from 17 to 84 years with a mean of 60 ± 17 years, the length of hospital stay ranged from 3 to 25 days with a mean of 11.5 ± 5 days,7 patients (17.5%) had thrombocytopenia (platelet count <150,000), 30 patients (75%) had normal platelet count (150,000-400,000) and only 3 patients (7.5%) had thrombocytosis (platelet count >400,000), 80% of the patients presented with lobar consolidation while the other 20% presented with multilobar consolidation, 50% of the included patients had type II respiratory failure, 30% had type I respiratory failure, while only 20% of the patients did not have respiratory failure, 47.5% of the patients did not develop any complications, 30% developed respiratory complications, 17.5% developed non-respiratory complications and 5% developed both respiratory and non-respiratory complications, and finally, 42.5% of the patients survived while 57.5% of them died. There was no significant relation between the different variables (gender, site of pneumonia, presence or absence of respiratory failure, the need for mechanical ventilation) and the mean of platelet count. Also, there was no significant correlation between the mean of platelet count versus age and length of hospital stay.
Importantly, there was a significant relation between the occurrence of respiratory complications (the majority was in the form of acute respiratory distress syndrome) and both thrombocytopenia and thrombocytosis. Moreover, there was a significant relation between both thrombocytopenia and thrombocytosis and the CURB65 score as a score for severity of CAP. These results are similar to those of Martinez et al. [8] , who conducted a 12 month prospective multicenter and longitudinal study in 10 hospitals of a Spanish Mediterranean area. They included hospitalized adult patients with CAP. They analyzed 1314 patients. Forty-three patients (3%) presented with thrombocytopenia, 107 (8%) thrombocytosis and 1164 (89%) had normal platelet count. Lower platelet counts were associated with an increase of severity of disease by PSI or CURB65. Patients with thrombocytopenia presented more often with severe sepsis and intensive care unit admission, whereas those with thrombocytosis presented more frequently with respiratory complications such as empyema. No association was found between abnormal platelet count and increased risk of mortality in the multivariable logistic regression model. They concluded that abnormal platelet count is associated with severity of disease and more frequently complications in patients with CAP.
On the other hand, the results of the present study showed that the overall mortality rate among the enrolled patients was 57.5%, among the patients with thrombocytopenia was 71.43%, among the patients with normal platelet count was 50% and among the patients with thrombocytosis was 100%. By defining a platelet count 150,000 as a cut-off point, the results of our study found that platelet count is considered better positive than a negative predictor to the outcome. This partially matches with the results of Georges et al. [9] , who conducted a multicenter retrospective study showing, in 822 patients admitted to an ICU for severe CAP, that severe thrombocytopenia (< 50,000 cells/lL) was an independent predictor of mortality. They looked at the impact of thrombocytosis in their patients. The overall ICU mortality rate was 35.4%. Thrombocytosis was present in 70 (5.7%) patients. They did not find any difference in outcome compared with patients with thrombocytosis. When considering the cause of death according to platelet numbers, they found it was essentially related to sepsis complications in patients with thrombocytopenia (septic refractory shock, n = 18; multi organ failure, n = 17; ARDS, n = 11; nosocomial pneumonia, Table 6 Relation between type of platelet count and outcome. n = 8), while in patients with thrombocytosis, the cause of death was mostly related to complications of ICU stay or associated co morbidity. Thus, they believed that thrombocytopenia remains an important predictor of outcome in patients with severe CAP. In these patients, thrombocytosis is not associated with worse outcome. The difference between the results of our study and those of Georges et al. might be due to the obvious discrepancy in the number of enrolled patients with thrombocytosis in both studies. On the contrary, Prina et al. [10] prospectively analyzed 2423 consecutive, hospitalized patients with CAP. They found that fifty-three patients (2%) presented with thrombocytopenia, 204 (8%) with thrombocytosis, and 2166 (90%) had normal platelet counts. Patients with thrombocytosis presented more frequently with respiratory complications, such as complicated pleural effusion and empyema, whereas those with thrombocytopenia presented more often with severe sepsis, septic shock, need for invasive mechanical ventilation and ICU admission. Patients with thrombocytosis and patients with thrombocytopenia had longer hospital stays and higher 30-day mortality and readmission rates than those with normal platelet counts. Multivariate analysis confirmed a significant association between thrombocytosis and 30-day mortality. Adding thrombocytosis to the confusion, respiratory rate, and BP plus age P65 years score slightly improved the accuracy to predict mortality (area under the receiver operating characteristic curve increased from 0.634 to 0.654, P = .049). They concluded that thrombocytosis in patients with CAP is associated with poor outcome, complicated pleural effusion, and empyema. The presence of thrombocytosis in CAP should encourage ruling out respiratory complication and could be considered for severity evaluation.
The results of our study are supported with those of Mirsaeidi et al. [11] , who conducted a retrospective cohort study of 500 consecutive patients admitted with CAP to the Veterans Administration Medical Center of Louisville, Kentucky, between June 2001 and March 2006. This study indicated that thrombocytopenia and thrombocytosis were significantly associated with mortality in patients with CAP. At the time of hospitalization, abnormalities in platelet count were better predictors of clinical outcomes in patients with CAP when compared with abnormalities in leukocyte count. On the other hand, when Cunha et al. [12] revised the results of Mirsaeidi et al., they were not at all convinced that the platelet count alone is a prognostic indicator in adults hospitalized with severe CAP. In both pieces, information was lacking regarding pathogen distribution, a key determinant of the platelet count. Because thrombocytopenia is not an acute-phase reactant, it cannot be said that thrombocytopenia with severe CAP is an indicator of severity and, thereby, is indirectly related to prognosis. Any CAP pathogen may present as severe CAP, depending on the cardiopulmonary and immune status of the host. Severity of CAP is largely related to these factors rather than to pathogen virulence per se. They also stated that if thrombocytopenia is present with bacterial CAP, clinicians should look for an alternate explanation (e.g., drug induced), or it may represent a complication (e.g., hemolytic uremic syndrome). In normal hosts, most CAP pathogens are not associated with either thrombocytopenia or thrombocytosis. Normal platelet counts are the rule among typical CAP pathogens, as well as among atypical CAP pathogens. In the absence of details on cardiopulmonary and humoral immune function as well as specific pathogen data, the platelet count is necessarily an imprecise prognostic indicator. In immunocompetent adults, it would seem that thrombocytopenia and thrombocytosis, rather than having a prognostic significance, may be more important diagnostically in suggesting a specific CAP pathogen.
Conclusion
A better understanding of the role of platelets in the outcomes of patients with pneumonia may generate new prognostic and therapeutic modalities for patients with severe disease.
Recommendations
1. Future research is needed to assess whether abnormality in platelet counts in patients with CAP is just a marker of the inflammatory response or is in part responsible for mortality. In particular, future research should focus on investigating the cause of death for patients with abnormal platelet counts. 2. Also, future researches should focus on the relation between platelet count abnormality and the causative pathogen of CAP. 3. When evaluating a complete blood count report in patients with CAP, platelet count may be informative for predicting patient poor outcomes in addition to the commonly used leukocyte count.
